Find an expert

Dr Bademosi received his BSc(Hons) in Medical Physiology from the University of Lagos (Nigeria) in 2010, and his MSc and PhD in Neuroscience from the Queensland Brain Institute at the University of Queensland in 2014 and 2018 respectively. He pioneered super-resolution single-molecule microscopy in vivo during his PhD, where he examined nanoscale changes in synaptic proteins during neurotransmission and under general anaesthesia. In 2018, obtained the highly competitive European Molecular Biology Organisation (EMBO) postdoctoral fellowship.to carry out his postdoctoral training in the lab of Professor Patrik Verstreken who is the current Director of of the Centre for Brain and Disease Research, Flemish Institute of Biotechnology, KU Leuven, Belgium. Here, he characterised how disease coding variants in risk genes for Parkinson's Disease elicit onset of neuronal degeneration (published in Neuron). Dr Bademosi was awarded the inaugural Race Against Dementia - Dementia Australia Research Foundation postdoctoral fellowship in 2020, to carry examine advanced nanoscale investigation into changes in the organisation and dynamics of the Motor Neuron Disease and Frontotemporal Dementia linked protein TDP-43. His research has been supported by grants from the Brain Foundation Australia, Dementia Australia Research Foundation, Motor Neuron Disease Research Institute of Australia, and the Australian Research Council.

I am a genetic epidemiologist specialising in the genetics of neurodegenerative diseases, with a particular focus on Parkinson’s disease, chronic pain, and other age-related conditions. I lead a dynamic team of scientists dedicated to understanding how genetic and environmental factors influence neurodegeneration, brain health, and related health outcomes. My research is interdisciplinary, integrating advanced statistical genetics, bioinformatics, and data science to unravel disease mechanisms, improve patient stratification, and identify potential therapeutic targets.

In 2020, I founded the Australian Parkinson’s Genetics Study (APGS), now the largest Parkinson’s cohort in Australia with over 10,000 participants. This landmark study has positioned Australia as a key contributor to global Parkinson’s genetics research. I am also actively involved in the Global Parkinson’s Genetics Program (GP2), where I contribute to large-scale data analysis and work within the underrepresented populations working group to enhance diversity in genetic research worldwide.

Committed to training the next generation of researchers, I have supervised over 16 students, including several PhD candidates who have gone on to successful careers in academia and industry. Two of my recent PhD graduates received the Outstanding Thesis Award, and another received the AIPS Florey Next Generation Award.

I have published consistently in prominent journals, including Nature, Nature Genetics, Nature Communications, BRAIN, Biological Psychiatry, and SLEEP. To date, I have authored over 100 academic articles, which have been widely cited, and I have secured competitive funding from NHMRC, MRFF, The Michael J. Fox Foundation for Parkinson’s Research, Shake It Up Australia Foundation, the US National Institutes of Health, and the Alzheimer’s Association. My work has been recognised with several prestigious awards, including the 2023 Al & Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation, the 2021 Enrico Greppi International Migraine Research Award, and the 2024 Adele Green Emerging Leader Award from QIMR Berghofer Medical Research Institute. I am also a Global Atlantic Fellow for Equity in Brain Health, a program by the University of California San Francisco and Trinity College Dublin, which supports my commitment to promoting brain health equity worldwide.

Dr Kirstine Shrubsole is an NHMRC Emerging Leadership Fellow at the Queensland Aphasia Research Centre. She holds a Bachelor of Speech Pathology (First Class Honours) from The University of Queensland, and completed her PhD in 2018. Kirstine has a research focus on improving implementation of evidence into practice in speech pathology and multidisciplinary services, with a special interest in stroke and aphasia rehabilitation. She has demonstrated that practice change is achievable for healthcare teams working in aphasia, leading to positive outcomes for patients, clinicians, and organisations.

Kirstine has published over 40 peer-reviewed journal articles, and has been awarded over $6 million in competitive research funding. Kirstine previously worked as the Conjoint Research Fellow in Speech Pathology (Princess Alexandra Hospital and The University of Queensland), providing research capacity building and mentoring to speech pathologists and supporting multidisciplinary research. Kirstine is the co-founder and Deputy Lead of the Collaboration of Aphasia Triallists’ Implementation Science in Aphasia working group, and a research affiliate of the Centre for Research Excellence in Aphasia Rehabilitation and Recovery.

Kirstine is completing a NHMRC Emerging Leadership Fellowship on the following topic:

• The Aphasia Implementation Toolkit Project: Developing an implementation intervention to improve services for stroke survivors with aphasia

She is a chief investigator on three MRFF grants, including:

• Unspoken, Unheard, Unmet: Improving Access to Preventative Health Care through Better Conversations about Care

• Bridging the Digital Divide: Building Health Self-Efficacy through Communication-Accessible Online Environments

• Enhancing utility of neuropsychological evaluation for earlier and effective diagnosis of dementia in Parkinson's disease

​Dr Tosolini is a cell biologist with a focus at the intersection of axonal transport, neurotrophic factors, motor neurons and skeletal muscle, in the context of motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS). His research to date has focused on utilising the connectivity between skeletal muscle and motor neurons for the enhanced delivery of therapeutic agents to the spinal cord (e.g., viral-mediated gene therapy). Building upon these foundations, his postdoctoral training focused on defining the axonal transport dynamics in a number of different experimental conditions, including stimulation with different neurotrophic factors (e.g., BDNF, GDNF), α motor neuron subtypes (i.e., fast motor neurons vs slow motor neurons), and alterations to such factors in MND/ALS pathology.

Dr Tosolini has joined the laboratories of A/Prof. Shyuan Ngo (AIBN) and Dr. Derek Steyn (SBMS) to undertake a novel project looking at assessing a novel therapeutic compound in mouse models of ALS, and in as well as in ALS patient-derived muscle cultures. This project is in collaboration with Dr. Giovanni Nardo at Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

​Dr Tosolini completed his PhD in 2015 in the discipline of Anatomy at the School of Medical Sciences, University of New South Wales (UNSW). His PhD project focused on characterising the connectivity between various skeletal muscles and their innervating motor neuron pools, to optimally deliver agents (e.g., retrograde tracers, virus) to the spinal cord motor neurons via retrograde axonal transport. For the work produced in his PhD, Dr Tosolini was awarded a place on the Faculty of Medicine's Dean's List.

In 2016, Dr Tosolini joined the Schiavo Laboratory at University College London (UCL), UK as a Post-Doctoral Research Associate to undertake a project focused on: 1) understanding factors influencing axonal transport dynamics in distinct in vitro and in vivo models of motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS), and 2) revealing the signalling elements governing neuronal trans-synaptic transfer.

In 2020, Dr Tosolini was awarded a Junior Non-Clinical Post-Doctoral Fellowship by the Motor Neuron Disease Association, UK to expand his work on evaluating axonal transport dynamics in mouse models of motor neuron disease (MND) as well as in diverse human induced pluripotent stem cell (hiPSC)-derived motor neurons. This project is a direct continuation of my post-doctoral training in the Schiavo laboratory, and included a novel collaboration with Prof. Rickie Patani (Francis Crick Institute, London, UK), to evaluate axonal transport dynamics of diverse organelles in mouse and human models of MND/ALS.

I am a cognitive neuroscientist with a research focus on the neural basis of language. My research is focused on three related questions:

1. How is language processed in the brain?
2. How does brain damage affect language processing in individuals with aphasia, i.e. acquired language disorders?
3. What brain mechanisms support the recovery of language processing in people with aphasia who improve over time?

To address these questions, my lab studies individuals with aphasia, as well as healthy participants with normal language, using a range of state-of-the-art functional and structural neuroimaging techniques. We combine our multimodal imaging approach with comprehensive language assessments designed to quantify deficits in different components of the language processing system, such as syntactic structure, word meanings, and the selection and assembly of speech sounds.

Language Neuroscience Laboratory